Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Medifast, Inc. reported revenue of $386M, down 36.0% year over year. Operating margin was -3.7% and net margin -4.8%, on a free-cash-flow margin of 0.3% with capital expenditure at 1.5% of revenue. Every figure is computed directly from MED's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $386M | -3.7% | -4.8% |
| FY2024 | $602M | 0.5% | 0.3% |
| FY2023 | $1.07B | 11.8% | 9.3% |
| FY2022 | $1.60B | 11.6% | 9.0% |
| FY2021 | $1.53B | 14.2% | 10.7% |
How does MED compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: BF-A · BGS · BRBR · BRID · BSFC · BYND
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.